Sanofi-Aventis is a global healthcare company dedicated to improving health and well-being through the development and production of a wide range of pharmaceutical products and vaccines. With a strong focus on research and innovation, the company operates in various therapeutic areas, including diabetes, oncology, cardiovascular disease, central nervous system disorders, immunology, and rare diseases. Sanofi-Aventis also emphasizes the importance of vaccines in disease prevention and offers a portfolio that addresses public health needs. The company strives to enhance patients' quality of life by providing effective treatments and advancing healthcare solutions worldwide. Read More
BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) ( Profile ) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and…
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are living with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (profile) is challenging that reality. The company is advancing Lucid-MS, a patented, first-in-class drug candidate that takes a fundamentally different approach by directly targeting the myelin sheath that MS destroys, and this new drug candidate is preparing to enter phase 2 clinical trials. Quantum BioPharma is one of several companies focused on the development and commercialization of therapies for neurological, autoimmune and immune-mediated diseases, including Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has entered into a definitive agreement to acquire the company. The all-cash transaction, valued at approximately $2.9 billion, represents a significant premium
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded (patented) pharmaceutical imports. The announcement, timed to coincide with the first anniversary of "Liberation Day"—the administration's 2025
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff on all imported patented pharmaceutical products. The aggressive trade measure is designed to force multinational drugmakers to shift production
In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines for approximately $2.175 billion. The deal marks Gilead’s second massive investment in the immunology sector within a
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the Cambridge-based biotechnology pioneer is mid-pivot into what CEO Stéphane Bancel describes as "Moderna 2.0." The company that once boasted a market capitalization exceeding $150 billion during the [...]
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing stellar long-term clinical data for its atopic dermatitis (eczema) treatment, Ebglyss. The disconnect between the laboratory and the trading
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster candidate, Tozorakimab. The positive data from the OBERON and TITANIA trials, which evaluated the drug in patients with moderate-to-severe chronic
CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years. The rally follows the release of breakthrough Phase 1/2 clinical data for its next-generation siRNA candidates, a development that
